Chemical Component Summary

Name3-[4-[2-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethyl-urea
SynonymsCariprazine
Identifiers3-[4-[2-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethyl-urea
FormulaC21 H32 Cl2 N4 O
Molecular Weight427.411
TypeNON-POLYMER
Isomeric SMILESCN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)c3cccc(c3Cl)Cl
InChIInChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17-
InChIKeyKPWSJANDNDDRMB-QAQDUYKDSA-N

Chemical Details

Formal Charge0
Atom Count60
Chiral Atom Count0
Bond Count62
Aromatic Bond Count6

Drug Info: DrugBank

DrugBank IDDB06016 
NameCariprazine
Groups
  • approved
  • investigational
DescriptionCariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors.[L40198] Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022.[L41670] It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]
Synonyms
  • trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochloride
  • Cariprazine
  • Cariprazine hydrochloride
Brand Names
  • Vraylar
  • Reagila
IndicationCariprazine is indicated for the treatment of **schizophrenia** in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (**bipolar mania**) in adults, and acute management of depressive episodes associated with bipolar I disorder (**bipolar depression**) in adults.[L43307,L40198]
Categories
  • Agents that produce hypertension
  • Antidepressive Agents
  • Antipsychotic Agents
  • Antipsychotic Agents (Second Generation [Atypical])
  • Central Nervous System Agents
ATC-CodeN05AX15
CAS number839712-12-8

Drug Targets

NameTarget SequencePharmacological ActionActions
Dopamine D3 receptorMASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV...unknownpartial agonist
Dopamine D2 receptorMDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF...unknownpartial agonist
5-hydroxytryptamine receptor 1AMDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCA...unknownpartial agonist
5-hydroxytryptamine receptor 2BMALSYRVSELQSTIPEHILQSTFVHVISSNWSGLQTESIPEEMKQIVEEQ...unknownantagonist
5-hydroxytryptamine receptor 2AMDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSE...unknownantagonist
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSD UWUYOC, UYOZEQ, UWUYOC01